Stock 003020 HEFEI LIFEON PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

All News Hefei Lifeon Pharmaceutical Co., Ltd.

Equities

003020

CNE100004BD9

End-of-day quote Shenzhen S.E.
Other stock markets
 23:00:00 02/06/2024 BST 		5-day change 1st Jan Change
21.19 CNY +1.00% Intraday chart for Hefei Lifeon Pharmaceutical Co., Ltd. +0.99% -9.67%
05-21 Lifeon Pharmaceutical's Unit Gets Marketing Authorization for Loxoprofen Sodium Oral Solution MT
04-29 Hefei Lifeon Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Lifeon Pharmaceutical's Unit Gets Marketing Authorization for Loxoprofen Sodium Oral Solution
MT
Hefei Lifeon Pharmaceutical Co., Ltd. Approves Cash Dividend for the Year 2023
CI
Hefei Lifeon Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Hefei Lifeon Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Lifeon Pharma’s Diabetes Drugs Pass China Consistency Evaluation
MT
Certain A Shares of Hefei Lifeon Pharmaceutical Co., Ltd. are subject to a Lock-Up Agreement Ending on 15-DEC-2023.
CI
Lifeon Pharmaceutical Gets Chinese Drug Regulator's Nod to Market Doxazosin Mesylate
MT
Hefei Lifeon Pharmaceutical Co., Ltd. Approves Election of Shi Jing as an Independent Director
CI
Hefei Lifeon Pharmaceutical Co., Ltd., Hefei Xinchen Enterprise Management Consulting Co., Ltd., Li Chao and Deng Xiaojuan agreed to acquire Hefei Noratech Pharmaceuticals Co., Ltd. from Roaring Success Ltd and Hefei Xinchen Enterprise Management Consulting Co., Ltd. for CNY 72 million.
CI
Hefei Lifeon Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
CI
Hefei Lifeon Pharmaceutical Co., Ltd.(XSEC:003020) added to S&P Global BMI Index
CI
Hefei Lifeon Pharmaceutical Co., Ltd. signed equity transfer agreement to acquire 51% stake in Anhui Joyfar Pharmaceutical Co. Ltd. from Beijing Huixu Jintong Investment Center (Limited Partnership), Beijing Huixu Jintai Investment Center (Limited Partnership), Gong Tonglin, Shen Jun, Zhao Shoutian and Ouyang Hanlin for approximately CNY 220 million.
CI
Hefei Lifeon Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Hefei Lifeon Pharmaceutical Co., Ltd. Declares Cash Dividend on A Shares for 2022, Payable on May 24, 2023
CI
Hefei Lifeon Pharmaceutical Co., Ltd. Approves Cash Dividend for the Year 2023
CI
Hefei Lifeon Pharmaceutical Co., Ltd. Proposes Final Dividend for 2022
CI
Hefei Lifeon Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Hefei Lifeon Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Hefei Lifeon Pharma’s Blood Pressure Drug Joins Bid For Inclusion in China’s Drug Procurement Program
MT
Worldunion Group CFO Resigns; Successor Named
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 003020 Stock
  4. News Hefei Lifeon Pharmaceutical Co., Ltd.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW